Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STRO 
Sutro Biopharma (STRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: STRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.87M USD | Price to earnings Ratio - | 1Y Target Price 3.43 |
Price to earnings Ratio - | 1Y Target Price 3.43 | ||
Volume (30-day avg) 1756223 | Beta 1.22 | 52 Weeks Range 0.58 - 5.28 | Updated Date 04/1/2025 |
52 Weeks Range 0.58 - 5.28 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.955 | Actual -0.6332 |
Profitability
Profit Margin - | Operating Margin (TTM) -440.66% |
Management Effectiveness
Return on Assets (TTM) -34.74% | Return on Equity (TTM) -234.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -243869536 | Price to Sales(TTM) 1 |
Enterprise Value -243869536 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 0.41 | Shares Outstanding 83775296 | Shares Floating 75352564 |
Shares Outstanding 83775296 | Shares Floating 75352564 | ||
Percent Insiders 4.1 | Percent Institutions 73.94 |
Analyst Ratings
Rating 4.55 | Target Price 11.5 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sutro Biopharma
Company Overview
History and Background
Sutro Biopharma, founded in 2003, is a clinical-stage drug discovery, development and manufacturing company. It focuses on oncology and autoimmune disorders using its cell-free protein synthesis platform, XpressCFu00ae, and site-specific conjugation, XpressCFu00ae+.
Core Business Areas
- Drug Discovery and Development: Sutro Biopharma focuses on discovering and developing antibody-drug conjugates (ADCs) and bispecific antibodies for cancer therapy.
- Manufacturing: The company also engages in the manufacturing of clinical trial material and commercial products through partnerships.
- Platform Technology: Sutro develops and uses its XpressCFu00ae and XpressCFu00ae+ platforms for improved antibody and ADC designs.
Leadership and Structure
The leadership team includes Bill Newell (CEO), Arturo Molina (CMO), and Jane Chung (CFO). The company is structured around research and development, clinical operations, and manufacturing.
Top Products and Market Share
Key Offerings
- STRO-002: An antibody-drug conjugate (ADC) targeting folate receptor alpha (FolRu03b1). It is being evaluated in clinical trials for ovarian cancer and endometrial cancer. Revenue from this product is currently negligible as it is still in clinical trials. Competitors include ImmunoGen (ELAHERE) and others developing FolRu03b1-targeted therapies.
- STRO-003: An antibody-drug conjugate (ADC) targeting ROR1. Currently in phase 1 clinical trial for hematological malignancies and solid tumors. Revenue from this product is currently negligible as it is still in clinical trials. Competitors include NBE-Therapeutics and others developing ROR1-targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The ADC market is growing significantly.
Positioning
Sutro Biopharma is positioned as an innovative company with a proprietary technology platform for ADC development. It holds a competitive advantage in the creation and manufacturing of unique ADCs.
Total Addressable Market (TAM)
The total addressable market for ADCs is expected to reach billions of dollars. Sutro Biopharma aims to capture a significant share of this market by developing innovative ADC therapies.
Upturn SWOT Analysis
Strengths
- Proprietary XpressCFu00ae and XpressCFu00ae+ technology platforms
- Strong pipeline of ADC and bispecific antibody candidates
- Manufacturing capabilities
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- Limited revenue stream compared to larger pharmaceutical companies
- High research and development expenses
- Dependence on partnerships for funding
Opportunities
- Potential for breakthrough therapies in oncology and autoimmune diseases
- Expansion of partnerships with pharmaceutical companies
- Advancement of clinical programs to regulatory approval
- Application of technology platform to new therapeutic areas
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies with greater resources
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- IMGN
- MRNA
- BGEN
- MYOV
- ALNY
- ARWR
- AVXL
- BLUE
- CRSP
- EDIT
- NTLA
- INMD
Competitive Landscape
Sutro Biopharma has a focused approach with ADC technology, distinguishing it from larger, diversified pharmaceutical companies. However, these larger companies have substantially more resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical milestones and partnerships, resulting in fluctuations.
Future Projections: Future growth projections are dependent on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing STRO-002 and STRO-003 clinical trials, securing partnerships, and expanding the pipeline.
Summary
Sutro Biopharma is a clinical-stage company with a promising ADC technology platform and a diverse pipeline. Success is dependent on clinical trial outcomes and regulatory approvals. The company's partnerships provide financial support, but it faces competition from larger pharmaceutical companies. Sutro needs to successfully navigate clinical trials and regulatory approval process while seeking to expand its strategic partnerships.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
ARWR
Arrowhead Pharmaceuticals Inc
ARWR
Arrowhead Pharmaceuticals Inc
AVXL
Anavex Life Sciences Corp
AVXL
Anavex Life Sciences Corp
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
INMD
InMode Ltd
INMD
InMode Ltd
MRNA
Moderna Inc
MRNA
Moderna Inc
NTLA
Intellia Therapeutics Inc
NTLA
Intellia Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sutro Biopharma
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-09-27 | CEO & Director Ms. Jane Chung R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 310 | Website https://www.sutrobio.com |
Full time employees 310 | Website https://www.sutrobio.com | ||
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.